Pharmacotherapy of Down's syndrome: When and Which?
Down syndrome (DS) is an important genetic disease that besides cerebral functions involves many other body systems. The postnatal approach to treat this genetic disease includes intervention on various related diseases (e.g. heart failure, respiratory, oral, ear and hearing disorders). Different treatments proposed barely improve the quality of life of these subjects. Another approach to the treatment of DS considering the possibility to intervene on the embryo was recently proposed. This paper has reviewed different aspects of DS and has analyzed the results of DS treatment in an animal model, namely the Ts65Dn mouse. Different treatment strategies tried to include genetic modification or treatment with vasoactive intestinal peptide derivatives or fluoxetine. The results obtained encourage to spend more time, efforts and resources in this field. The main obstacle to the use of these possible treatments is in the ethic problems that they raise. In fact, the progression of the pregnancy in spite of awareness that the unborn is affected by DS and prenatal treatment of DS injured embryo are relevant dilemmas. In view of this, more efforts should be spent by talented researchers and in the best research facilities to improve the quality of life to people affected by DS. These efforts will allow probably a better approach to ethic issues.